Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$2.77
-1.1%
$2.86
$2.00
$5.00
$11.61M2.1371,339 shs80,225 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$1.50
-2.1%
$0.96
$0.64
$2.92
$60.41M-0.8325,553 shs400,864 shs
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$10.68
-5.2%
$8.93
$2.31
$13.70
$37.53M-0.63121,723 shs39,027 shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.67
-2.7%
$0.77
$0.58
$5.54
$26.64M-0.78314,230 shs411,673 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
0.00%-7.05%+1.67%+0.73%-24.01%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%+46.11%+67.52%+105.18%-0.17%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00%+13.48%+38.34%+6.80%+83.13%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
0.00%+6.69%-6.49%-43.58%-87.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ainos, Inc. stock logo
AIMD
Ainos
0.8416 of 5 stars
0.05.00.00.00.01.70.6
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.3695 of 5 stars
3.55.00.00.02.30.81.3
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.2087 of 5 stars
0.03.00.00.00.01.70.0
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.2558 of 5 stars
3.65.00.00.01.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ainos, Inc. stock logo
AIMD
Ainos
0.00
N/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$6.25317.33% Upside
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00
N/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.20
Buy$13.001,836.25% Upside

Current Analyst Ratings Breakdown

Latest AIMD, BRNS, FBLG, and COEP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/17/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/15/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ainos, Inc. stock logo
AIMD
Ainos
$20K580.32N/AN/A$5.51 per share0.50
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M4.04N/AN/A$3.23 per share0.46
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/A$1.61 per shareN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$6.45N/AN/AN/A-88.07%-48.60%8/4/2025 (Estimated)
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$10.88M-$5.80N/AN/AN/A-282.39%-127.23%N/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)

Latest AIMD, BRNS, FBLG, and COEP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.33N/AN/AN/AN/AN/A
8/6/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.11N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A-$1.11N/A-$1.11N/AN/A
5/13/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.10-$0.14-$0.04-$0.14N/AN/A
5/12/2025Q1 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$1.05N/A-$0.21N/A$0.11 million
5/7/2025Q1 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ainos, Inc. stock logo
AIMD
Ainos
0.84
2.00
1.91
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
9.18
9.18
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.02
0.82
0.82
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
1.14
1.14

Institutional Ownership

CompanyInstitutional Ownership
Ainos, Inc. stock logo
AIMD
Ainos
N/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A

Insider Ownership

CompanyInsider Ownership
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10.70%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
24.25%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
20.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ainos, Inc. stock logo
AIMD
Ainos
404.19 million3.76 millionNot Optionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million36.02 millionN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
23.51 million2.66 millionNot Optionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1039.68 million31.75 millionN/A

Recent News About These Companies

FibroBiologics, Inc. (FBLG) - Yahoo Finance
FibroBiologics Appoints Jason D. Davis as CFO
FibroBiologics announces CFO appointment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ainos stock logo

Ainos NASDAQ:AIMD

$2.77 -0.03 (-1.07%)
As of 07/18/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$1.50 -0.03 (-2.12%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$1.47 -0.03 (-1.84%)
As of 07/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Coeptis Therapeutics stock logo

Coeptis Therapeutics NASDAQ:COEP

$10.68 -0.58 (-5.15%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.99 +0.31 (+2.90%)
As of 07/18/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.67 -0.02 (-2.70%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.67 0.00 (-0.21%)
As of 07/18/2025 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.